**a. Background and Purpose:** The Middle East respiratory syndrome coronavirus (MERS-CoV) is ubiquitous in dromedary camels. Several studies reported the high seroprevalence of MERS-COV among dromedary camels in the Middle East and Africa. Furthermore, it was not clear if the previously infected animals could be further infected if exposed to the virus for the second or third time. The reasons behind these phenomena still require more explanation. We conducted a longitudinal study to answer these important questions and provide some clues on the potential vaccination strategies for dromedary camels against MERS-CoV.

**b. Methodology:** Two herds of dromedary camels were longitudinally sampled with nasal and rectal swabs and serum, between September 2014 and May 2015, and the samples were tested for Middle East Respiratory Syndrome (MERS) coronavirus RNA and antibodies.

**c. Results and Discussions:** Evidence of MERS-CoV infection was confirmed in one herd on the basis of detection of virus RNA in nasal swabs from three camels and significant increases in the antibody titers from three others. The three viruses were genetically identical, thus indicating introduction of a single virus into this herd.

**d. Conclusions:** There was evidence of reinfection of camels that were previously seropositive, thus suggesting that prior infection does not provide complete immunity from reinfection, a finding that is relevant to camel vaccination strategies as a means to prevent zoonotic transmission.
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